ScreenerHero

INBX Inhibrx Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · inhibrx.com
93.36USD-0.05%Mkt Cap: 1.37B $P/E: —

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.37B USD
Enterprise Value1.42B USD
Revenue (TTM)0 USD
Gross Profit-103.00M USD
Net Income (TTM)-140.06M USD
Revenue/Share0.00 USD
Last Price93.36 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees109
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.66
PEG—
EV/EBITDA-11.33
EV/Revenue—
P/SInfinity
P/B-25.93
EPS (TTM)-8.88
EPS (Forward)-8.76
52W Range
28.1651% of range155.29
52W High155.29 USD
52W Low28.16 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-10773.46%
ROE-1752.22%
ROA-95.62%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-129.79M USD
CapEx (TTM)31.00K USD
FCF Margin—
FCF Yield-6.19%
Net Debt48.28M USD
Net Debt/EBITDA-0.38
Balance Sheet
Debt/Equity13.39
Current Ratio5.07
Quick Ratio4.76
Book Value/Sh-3.60 USD
Cash/Share9.06 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)266.67 USD
Upside (mean)+185.6%
Target Range230.00 USD – 325.00 USD
230.00+185.6% to mean325.00
# Analysts3
Ownership
Shares Out.14.72M
Float8.59M
Insiders23.08%
Institutions90.61%
Short Interest
Short Ratio9.2d
Short % Float30.78%
Short % Out.23.06%
Shares Short3.39M
Short (prev mo.)3.22M
Technical
SMA 50102.24 (-8.7%)
SMA 20091.14 (+2.4%)
Beta3.82
S&P 52W Chg16.45%
Avg Vol (30d)315.62K
Avg Vol (10d)255.52K
Technical Indicators
RSI (14)37.6
MACD-2.6389
MACD Signal-0.6836
MACD Hist.-1.9553
BB Upper117.86 USD
BB Middle103.96 USD
BB Lower90.06 USD
BB Width26.74%
ATR (14)6.744 USD
Vol Ratio (20d)0.64x